Show simple item record

dc.contributor.authorEmsley, Robin
dc.contributor.authorHarvey, Brian H.
dc.contributor.authorChiliza, Bonginkosi
dc.contributor.authorAsmal, Laila
dc.contributor.authorDu Plessis, Stefan
dc.date.accessioned2016-02-25T09:48:06Z
dc.date.available2016-02-25T09:48:06Z
dc.date.issued2014
dc.identifier.citationEmsley, R. et al. 2014. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophrenia research, 158(1-3):230-235. [https://doi.org/10.1016/j.schres.2014.06.004]en_US
dc.identifier.issn0920-9964
dc.identifier.urihttp://hdl.handle.net/10394/16426
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S092099641400293X
dc.identifier.urihttps://doi.org/10.1016/j.schres.2014.06.004
dc.description.abstractBackground: While antipsychotics are effective in the maintenance treatment of schizophrenia they have safety and tolerability risks. We investigated whether a combination of omega-3 polyunsaturated fatty acids (ω−3 PUFAs) and a metabolic antioxidant, alpha-lipoic acid (α-LA), is effective in preventing relapse after antipsychotic discontinuation in subjects who were successfully treated for 2–3 years after a first-episode of schizophrenia, schizo-affective or schizophreniform disorder. Methods: In this randomized, double-blind, placebo controlled study antipsychotic treatment was tapered and discontinued and participants received either ω−3 PUFAs (eicosapentaenoic acid 2 g/day and docosahexaenoic acid 1 g/day) + α-LA 300 mg/day or placebo. Subjects were followed up for two years, or until relapse. Results: Recruitmentwas terminated prematurely due to the high relapse rates in both treatment groups as well as the severity of some of the relapse episodes. Of the 33 participants, 19/21(90%) randomized to ω−3 PUFAs+α-LA relapsed and one (5%) completed two years without relapse (p = 0.6); and 9/12 (75%) randomized to placebo relapsed and none completed two years without relapse. Mean times to relapse were 39.8 ± 25.4 and 38.3 ± 26.6 weeks for the ω−3 PUFAs + α-LA and placebo groups, respectively (p = 0.9). There were no significant differences between the groups in relapse symptom severity. Conclusions: We found no evidence that ω−3 PUFAs + α-LA could be a suitable alternative to maintenance antipsychotic treatment in relapse prevention, in this small study. Antipsychotic discontinuation after a single episode of schizophrenia carries a very high risk of relapse, and treatment guidelines endorsing this practice should be reviseden_US
dc.description.sponsorshipStanley Medical Research Institute (Grant #09T-1281)en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectSchizophreniaen_US
dc.subjectRelapse-preventionen_US
dc.subjectOmega-3en_US
dc.subjectAntioxidanten_US
dc.subjectPlaceboen_US
dc.titleA randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophreniaen_US
dc.typeArticleen_US
dc.contributor.researchID11083417 - Harvey, Brian Herbert


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record